Research
Hormonal
Once-monthly maridebart has produced clinically meaningful weight loss of approximately 12–16% in adults without diabetes and 8–12% in those with type 2 diabetes.
Practitioners can expect significant weight loss outcomes with once-monthly maridebart in their patients.
StrongSupportsmedium confidence
Across phase 2 trials, once-monthly maridebart has produced clinically meaningful weight loss (~12–16% in adults without diabetes; ~8–12% in those with T2D).
Why this rating
Based on phase 2 trials, indicating a high level of evidence.
Source
Once-Monthly and Extended-Interval Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines
Héctor Iván Saldívar-Cerón · Scientia Pharmaceutica · 2026
other
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →